Tag: Cancer: Leukemia
ASH: Blinatumomab + Chemo Aids Survival in B-Cell Acute Lymphoblastic Leukemia
Estimated disease-free survival 97.5 ± 1.3 and 90.2 ± 2.3 percent with chemotherapy plus blinatumomab, chemo alone in average-risk patients
Durable Response High With Obe-Cel in B-Cell Acute Lymphoblastic Leukemia
Overall remission occurred in 77 percent of patients in a cohort with morphologic disease
COVID-19 Mortality Higher for Leukemia, Myelodysplastic Syndrome Patients
However, risk for hospitalization no higher for COVID-19 in these patients
Radon Exposure Tied to Higher Risk for Childhood Leukemia
Findings seen even for exposure below the U.S. Environmental Protection Agency guidelines
Measurable Residual Disease Results After Consolidation Therapy Predictive of Relapse in Pediatric Leukemia
Patients who are measurable residual disease-negative at end of first consolidation do not need subsequent MRD measurements
High Health Care Utilization, Poor Survival Seen for Over 70s With AML
Of patients who died during observation, median of 56 percent of time between diagnosis and death spent in hospital
Pharmacogenomic Score Can Personalize Treatment of Leukemia in Children
Patients in low ACS10 score group have significantly improved survival with clofarabine+cytarabine treatment
Blinatumomab + Chemo Ups Survival in B-Cell Precursor Acute Lymphoblastic Leukemia
Improved overall survival and three-year relapse-free survival seen with blinatumomab plus chemo for adult patients
German Patient is 7th Person Probably Cured of HIV
Ophthalmologic Manifestations of Acute Leukemia Are Heterogeneous
Most common ocular manifestations are retinal hemorrhage and Roth spots
